An evaluation of potential neuroprotective strategies in rats with partial MPP+ or 6-OHDA lesions of the substantia nigra

Restorative and neuroprotective treatment strategies for Parkinson’s disease: tudies on fetal dopamine cell transplants and GDNF delivery by intracerebral injections and recombinant AAV vectors.

Kirik, Deniz

January 2001

The intrastriatal 6-hydroxydopamine lesion model in rats is particularly useful in studies testing n...

Neonatal 6-Hydroxydopamine Lesioning of Rats and Dopaminergic Neurotoxicity: Proposed Animal Model of Parkinson\u27s Disease

Kostrzewa, Richard M.

March 2022

The neurotoxin 6-hydroxydopamine (6-OHDA), following pretreatment with the norepinephrine transport ...

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

Austin, P. J.
Betts, M. J.
Broadstock, M.
O&apos
Mitchell, S. N.
Duty, S.

August 2010

Background and purpose: Increased glutamatergic innervation of the substantia nigra pars reticulata ...

Neuroprotection against excitotoxic cell damage in rat striatum and hippocampus

Arvin, B

January 1989

SIGLEAvailable from British Library Document Supply Centre- DSC:DX93755 / BLDSC - British Library Do...

Quantification of TH and NeuN in the dopaminergic system after 6-OHDA lesioning.

Anne Michel (675469)
Patrick Downey (675470)
Jean-Marie Nicolas (675471)
Dieter Scheller (675472)

December 2014

<p>Intensity of TH and NeuN positive immunostaining of the substantia nigra pars compacta (left) and...

Evaluation of new treatment strategies for Parkinson's disease in animal models : the therapeutic efficacy of the dopamine D1 antagonist SKF 83959 and the neuroprotective agent CGP 3466B

Andringa, Gerda

January 2000

Parkinson's disease is a progressive neurodegenerative disorder, characterized by a loss of dopamine...

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease

Bridget Martinez
Philip V Peplow

January 2018

Parkinson’s disease (PD) is an age-related neurodegenerative disease for which the characteristic mo...

Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures

FULCERI F
BIAGIONI F
LENZI P
FALLENI A
GESI M
RUGGIERI S
FORNAI F

January 2006

The 6-hydroxydopamine (6-OHDA) model of Parkinson's disease in the rat represents a fundamental tool...

6-OHDA lesion models of Parkinson’s disease in the rat

Torres, Eduardo Miguel
Dunnett, Stephen Bruce

January 2012

The 6-hydroxydopamine (6-OHDA) lesion of the rat nigrostriatal pathway is the most widely used anima...

Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease

Armentero M. -T.
Levandis G.
Nappi G.
Bazzini E.
Blandini F.

January 2006

Complete Freund's adjuvant (CFA), a pro-inflammatory agent, was inoculated, subcutaneously, to Sprag...

Neuroprotective effects and mechanisms of the activation of group III metabotropic glutamate receptor in rodent models of Parkinson's disease

Buckingham, Julia
Chan, Hugh Hiu-Nam

January 2010

Current therapy for PD is focused on dopamine replacement by the use of L-DOPA and dopamine agonists...

A partial lesion model of Parkinson's disease in mice - Characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Boix, Jordi
Padel, Thomas
Paul-Visse, Gesine

January 2015

The most frequently used animal models for Parkinson's disease (PD) utilize unilateral injection of ...

Neuroprotection and Neurogenesis in the Rat's 6-OHDA-Model of Parkinson's Disease after Therapeutic Intervention

Hosmann, Kai

January 2009

Die hochfrequente Tiefenhirnstimulation des Nucleus subthalamicus (STN) ist ein etabliertes Therapie...

Exercise induced neuroprotection in spontaneuosly running rats

Mabandla, Musa Vuyisile

January 2007

Includes bibliographical references (p. 182-205).We investigated the effects of voluntary exercise o...

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

Armentero M. -T.
Fancellu R.
Nappi G.
Bramanti P.
Blandini F.

January 2006

We compared the neuroprotective and metabolic effects of chronic treatment with ionotropic or metabo...

Restorative and neuroprotective treatment strategies for Parkinson’s disease: tudies on fetal dopamine cell transplants and GDNF delivery by intracerebral injections and recombinant AAV vectors.

Kirik, Deniz

January 2001

The intrastriatal 6-hydroxydopamine lesion model in rats is particularly useful in studies testing n...

Neonatal 6-Hydroxydopamine Lesioning of Rats and Dopaminergic Neurotoxicity: Proposed Animal Model of Parkinson\u27s Disease

Kostrzewa, Richard M.

March 2022

The neurotoxin 6-hydroxydopamine (6-OHDA), following pretreatment with the norepinephrine transport ...

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

Austin, P. J.
Betts, M. J.
Broadstock, M.
O&apos
Mitchell, S. N.
Duty, S.

August 2010

Background and purpose: Increased glutamatergic innervation of the substantia nigra pars reticulata ...

Neuroprotection against excitotoxic cell damage in rat striatum and hippocampus

Arvin, B

January 1989

SIGLEAvailable from British Library Document Supply Centre- DSC:DX93755 / BLDSC - British Library Do...

Quantification of TH and NeuN in the dopaminergic system after 6-OHDA lesioning.

Anne Michel (675469)
Patrick Downey (675470)
Jean-Marie Nicolas (675471)
Dieter Scheller (675472)

December 2014

<p>Intensity of TH and NeuN positive immunostaining of the substantia nigra pars compacta (left) and...

Evaluation of new treatment strategies for Parkinson's disease in animal models : the therapeutic efficacy of the dopamine D1 antagonist SKF 83959 and the neuroprotective agent CGP 3466B

Andringa, Gerda

January 2000

Parkinson's disease is a progressive neurodegenerative disorder, characterized by a loss of dopamine...

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease

Bridget Martinez
Philip V Peplow

January 2018

Parkinson’s disease (PD) is an age-related neurodegenerative disease for which the characteristic mo...

Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures

FULCERI F
BIAGIONI F
LENZI P
FALLENI A
GESI M
RUGGIERI S
FORNAI F

January 2006

The 6-hydroxydopamine (6-OHDA) model of Parkinson's disease in the rat represents a fundamental tool...

6-OHDA lesion models of Parkinson’s disease in the rat

Torres, Eduardo Miguel
Dunnett, Stephen Bruce

January 2012

The 6-hydroxydopamine (6-OHDA) lesion of the rat nigrostriatal pathway is the most widely used anima...

Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease

Armentero M. -T.
Levandis G.
Nappi G.
Bazzini E.
Blandini F.

January 2006

Complete Freund's adjuvant (CFA), a pro-inflammatory agent, was inoculated, subcutaneously, to Sprag...

Neuroprotective effects and mechanisms of the activation of group III metabotropic glutamate receptor in rodent models of Parkinson's disease

Buckingham, Julia
Chan, Hugh Hiu-Nam

January 2010

Current therapy for PD is focused on dopamine replacement by the use of L-DOPA and dopamine agonists...

A partial lesion model of Parkinson's disease in mice - Characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Boix, Jordi
Padel, Thomas
Paul-Visse, Gesine

January 2015

The most frequently used animal models for Parkinson's disease (PD) utilize unilateral injection of ...

Neuroprotection and Neurogenesis in the Rat's 6-OHDA-Model of Parkinson's Disease after Therapeutic Intervention

Hosmann, Kai

January 2009

Die hochfrequente Tiefenhirnstimulation des Nucleus subthalamicus (STN) ist ein etabliertes Therapie...

Exercise induced neuroprotection in spontaneuosly running rats

Mabandla, Musa Vuyisile

January 2007

Includes bibliographical references (p. 182-205).We investigated the effects of voluntary exercise o...

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

Armentero M. -T.
Fancellu R.
Nappi G.
Bramanti P.
Blandini F.

January 2006

We compared the neuroprotective and metabolic effects of chronic treatment with ionotropic or metabo...

Restorative and neuroprotective treatment strategies for Parkinson’s disease: tudies on fetal dopamine cell transplants and GDNF delivery by intracerebral injections and recombinant AAV vectors.

Kirik, Deniz

January 2001

The intrastriatal 6-hydroxydopamine lesion model in rats is particularly useful in studies testing n...

Neonatal 6-Hydroxydopamine Lesioning of Rats and Dopaminergic Neurotoxicity: Proposed Animal Model of Parkinson\u27s Disease

Kostrzewa, Richard M.

March 2022

The neurotoxin 6-hydroxydopamine (6-OHDA), following pretreatment with the norepinephrine transport ...

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

Austin, P. J.
Betts, M. J.
Broadstock, M.
O&apos
Mitchell, S. N.
Duty, S.

August 2010

Background and purpose: Increased glutamatergic innervation of the substantia nigra pars reticulata ...

An evaluation of potential neuroprotective strategies in rats with partial MPP+ or 6-OHDA lesions of the substantia nigra

Abstract

Extracted data

An evaluation of potential neuroprotective strategies in rats with partial MPP+ or 6-OHDA lesions of the substantia nigra

Abstract

Extracted data

Related items

Related items